combination therapy

News
First-Line Biosimilar-Based Triplet Effective in HER2-Positive Gastric Cancer
07/08/2020
A first-line triplet regimen consisting of pembrolizumab, biosimilar trastuzumab (Herzuma), and chemotherapy is effective in patients with HER2-positive advanced gastric cancer, according to the results of a phase...
A first-line triplet regimen consisting of pembrolizumab, biosimilar trastuzumab (Herzuma), and chemotherapy is effective in patients with HER2-positive advanced gastric cancer, according to the results of a phase...
A...
07/08/2020
Journal of Clinical Pathways
News
Isatuximab Combination Effective in Myeloma and Soft-Tissue Plasmacytomas
06/22/2020
Isatuximab plus pomalidomide and dexamethasone (Isa-Pd) significantly prolongs progression-free survival (PFS) and improves overall response rate (ORR) compared with pomalidomide plus dexamethasone alone (Pd) in...
Isatuximab plus pomalidomide and dexamethasone (Isa-Pd) significantly prolongs progression-free survival (PFS) and improves overall response rate (ORR) compared with pomalidomide plus dexamethasone alone (Pd) in...
...
06/22/2020
Journal of Clinical Pathways
News
Venetoclax-Based Time-Limited Therapy Well Tolerated, Effective in CLL
06/10/2020
Zanubrutinib plus venetoclax and obinutuzumab is well tolerated and achieves rapid undetectable minimal residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL), according to a presentation at the...
Zanubrutinib plus venetoclax and obinutuzumab is well tolerated and achieves rapid undetectable minimal residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL), according to a presentation at the...
...
06/10/2020
Journal of Clinical Pathways
Research in Review
Internal Radiotherapy Combined With Chemo in Colorectal Liver Metastasis
08/09/2017
JCP Editors
A recent study combined and analyzed data from three trials regarding the use of first-line chemotherapy plus selective internal radiotherapy in patients with colorectal cancer and liver metastases, published in The...
A recent study combined and analyzed data from three trials regarding the use of first-line chemotherapy plus selective internal radiotherapy in patients with colorectal cancer and liver metastases, published in The...
A...
08/09/2017
Journal of Clinical Pathways
Research in Review
Combination Therapy Improves Survival in a Subtype of AML
08/04/2017
JCP Editors
Addition of a multi-targeted kinase inhibitor to standard chemotherapy improves outcomes in patients with acute myeloid leukemia (AML) and a specific mutation, according to research published in The New England...
Addition of a multi-targeted kinase inhibitor to standard chemotherapy improves outcomes in patients with acute myeloid leukemia (AML) and a specific mutation, according to research published in The New England...
...
08/04/2017
Journal of Clinical Pathways
Research in Review
Combination Therapy Works Better in AML Patients With Activated NK Cells
08/03/2017
JCP Editors
The presence of natural killer cells can help keep acute myeloid leukemia (AML) in remission in patients treated with a combination therapy, according to a recent study. ----- Related Content Better AML Outcomes...
The presence of natural killer cells can help keep acute myeloid leukemia (AML) in remission in patients treated with a combination therapy, according to a recent study. ----- Related Content Better AML Outcomes...
The...
08/03/2017
Journal of Clinical Pathways
Research in Review
ADT Plus Combination Therapy Improves Outcomes in Metastatic Prostate Cancer
07/28/2017
JCP Editors
A combination regimen plus androgen-deprivation therapy prolongs overall survival (OS) and radiographic progression-free survival (PFS) in newly diagnosed patients with metastatic, castration-sensitive prostate...
A combination regimen plus androgen-deprivation therapy prolongs overall survival (OS) and radiographic progression-free survival (PFS) in newly diagnosed patients with metastatic, castration-sensitive prostate...
A...
07/28/2017
Journal of Clinical Pathways
Research in Review
Triplet Combination Shows Durable Responses in Advanced Multiple Myeloma
07/17/2017
JCP Editors
Patients with heavily treated multiple myeloma showed rapid and durable responses to a novel treatment combination, according to a recent study published in Blood (July 2017;...
Patients with heavily treated multiple myeloma showed rapid and durable responses to a novel treatment combination, according to a recent study published in Blood (July 2017;...
...
07/17/2017
Journal of Clinical Pathways
Research in Review
Adjuvant Ovarian Function Suppression Improves Breast Cancer Treatment Outcomes
06/29/2017
JCP Editors
In younger women with hormone receptor (HR)-positive breast cancer, ovarian function suppression (OFS) after surgery drives large improvements in breast cancer-free interval when combined with drug therapy, according...
In younger women with hormone receptor (HR)-positive breast cancer, ovarian function suppression (OFS) after surgery drives large improvements in breast cancer-free interval when combined with drug therapy, according...
In...
06/29/2017
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use